Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression

Journal of Neuro-Oncology

Volumn 112, Issue 3, 2013, Pages 413-420

  Agarwal, Ajay ^a   Kumar, Sanath ^a   Narang, Jayant ^a   Schultz, Lonni ^a   Mikkelsen, Tom ^a   Wang, Sumei ^b   Siddiqui, Sarmad ^b   Poptani, Harish ^b   Jain, Rajan ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diffusion tensor imaging; Early tumor progression; Magnetic resonance imaging; Pseudo progression

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DOSIMETRY; EARLY TUMOR PROGRESSION; FEMALE; GLIOMA; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE DISTRIBUTION; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR GROWTH; TUMOR PSEUDO PROGRESSION; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOMETRY; RADIOTHERAPY;

EID: 84885066469     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1070-1     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organization for research and treatment of cancer, brain tumor and radiotherapy groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461
3. Chamberlain MC, Glantz MJ, Chalmers L, van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81-83
4. de Wit MC, de Bruin HG, Eijkenboom W, SillevisSmitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535-537
5. Taal W, Brandsma D, de Bruin HG, Branberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Dent MJ (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405-410
6. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, Holodny AI, Omuro AM (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76:1918-1924
7. Jain R, Narang J, Arbab SA, Schultz L, Scarpace L, Mikkelsen T, Babajani-Feremi A (2011) Role of non-model-based semi-quantitative indices obtained from DCE T1 MR perfusion in differentiating pseudo-progression from true-progression. Neuro-Oncol 13:140
8. Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH (2011) Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine - DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 32:382-387
9. Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG, Njus JM, Haluska M, Neuwelt EA (2011) Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility- weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 79:514-523
10. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, DiChiro G (1996) Diffusion tensor MR imaging of the human brain. Radiology 201:637-648
11. Stadlbauer A, Ganslandt O, Buslei R, Hammen T, Gruber S, Moser E, Buchfelder M, Salomonowitz E, Nimsky C (2006) Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 240:803-810
12. Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D (2004) Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology 232:451-460
13. https://wiki.cancerimagingarchive.net/x/wgEe Accessed 11 Nov 2011
14. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P (1997) Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16:187-198
15. Ashburner J, Friston KJ (1999) Nonlinear spatial normalization using basis functions. Hum Brain Mapp 7:254-266
16. Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, O'Rourke DM, Judy KD, Poptani H, Melhem ER (2011) Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 32:507-514
17. Wang S, Kim S, Chawla S, Wolf RL, Zhang WG, O'Rourke DM, Judy KD, Melhem ER, Poptani H (2009) Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 44:653-660
18. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635-1642
19. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197
20. Pouleau HB, Sadeghi N, Balériaux D, Melot C, DeWitte O, Lefranc F (2012) High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int J Oncol 40:923-928
21. Jain R, Scarpace L, Ellika S, Schultz LR, Rock JP, Rosenblum ML, Patel SC, Lee TY, Mikkelsen T (2007) First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 61:778-786
22. Jain R, Narang J, Schultz L, Scarpace L, Saksena S, Brown S, Rock JJ, Rosenblum M, Gutierrez J, Mikkelsen T (2011) Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol 32:658-663
23. Narang J, Jain R, Arbab SA, Mikkelsen T, Scarpace L, Rosenblum ML, Hearshen D, Babajani-Feremi A (2011) Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using non-model based semi-quantitative indices derived from dynamic contrast enhanced T1-weighted MR perfusion. Neuro-Oncol 13(9):1037-1046
24. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367-372
25. Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K, Kochi M, Morishita S, Yamashita Y (2005) Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 26:1455-1460
26. Sundgren PC, Fan X, Weybright P, Welsh RC, Carlos RC, Petrov M, McKeever PE, Chenevert TL (2006) Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 24:1131-1142
27. Zhang S, Bastin ME, Laidlaw DH, Sinha H, Armitage PA, Deisboeck TS (2004) Visualization and analysis of white matter structural asymmetry in diffusion tensor MRI data. Magn Reson Med 51:140-147
28. Rai V, Nath K, Saraswat VA, Purwar A, Rathore RK, Gupta RK (2008) Measurement of cytotoxic and interstitial components of cerebral edema in acute hepatic failure by diffusion tensor imaging. J Magn Reson Imaging 28:334-341
29. Saksena S, Jain R, Narang J, Scarpace L, Schultz LR, Rock JP, Rosenblum M, Patel SC, Mikkelsen T (2010) Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging 32:788-795
30. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MR, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
31. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79-88